Recro Pharma, Inc. (NASDAQ:REPH) has earned an average rating of “Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $13.50.

REPH has been the topic of a number of research analyst reports. Janney Montgomery Scott downgraded Recro Pharma from a “buy” rating to a “fair value” rating and cut their target price for the stock from $21.00 to $6.50 in a research note on Wednesday, June 14th. Zacks Investment Research downgraded Recro Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Piper Jaffray Companies set a $11.00 target price on Recro Pharma and gave the stock a “buy” rating in a research note on Tuesday, July 25th. Finally, Roth Capital set a $20.00 target price on Recro Pharma and gave the stock a “buy” rating in a research note on Monday, July 31st.

Recro Pharma (NASDAQ REPH) traded up 3.90% during mid-day trading on Wednesday, reaching $9.06. The company’s stock had a trading volume of 107,466 shares. Recro Pharma has a 52-week low of $5.81 and a 52-week high of $10.17. The firm has a 50 day moving average price of $8.14 and a 200 day moving average price of $7.72. The company’s market cap is $172.68 million.

Recro Pharma (NASDAQ:REPH) last announced its earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.06. Recro Pharma had a negative return on equity of 56.04% and a negative net margin of 46.75%. The firm had revenue of $16.93 million for the quarter, compared to the consensus estimate of $14.90 million. Equities research analysts anticipate that Recro Pharma will post ($2.35) earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its stake in Recro Pharma by 3.0% in the first quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock valued at $150,000 after purchasing an additional 500 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in Recro Pharma by 76.9% in the second quarter. Janney Montgomery Scott LLC now owns 22,085 shares of the specialty pharmaceutical company’s stock valued at $155,000 after purchasing an additional 9,600 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Recro Pharma in the first quarter valued at approximately $156,000. KCG Holdings Inc. purchased a new position in Recro Pharma in the first quarter valued at approximately $173,000. Finally, Rothschild Investment Corp IL purchased a new position in Recro Pharma in the second quarter valued at approximately $141,000. Institutional investors and hedge funds own 65.06% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Recro Pharma, Inc. (REPH) Given Consensus Rating of “Buy” by Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/11/recro-pharma-inc-reph-given-consensus-rating-of-buy-by-analysts.html.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.